Sierra Oncology, Inc.
- CIK
- 1290149
- Industry
- Pharmaceutical Preparations
- Based in
- San Mateo, California
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- SEC filer category
- Non-accelerated filer, Smaller reporting company
- Formerly
- ProNAi Therapeutics Inc
Key figures
| Fiscal year to | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|
| Revenue | – | $300.0K | – | – | – |
| Operating income | −$94.6M | −$64.9M | −$67.0M | −$55.4M | −$42.6M |
| Net income | −$94.7M | −$80.9M | −$88.3M | −$53.3M | −$42.0M |
| Diluted EPS | −$7.14 | −$7.70 | −$30.30 | −$30.16 | −$33.68 |
| Cash from operations | −$79.0M | −$52.4M | −$51.2M | −$45.1M | −$36.2M |
| Total assets | $109.4M | $107.5M | $151.3M | $109.5M | $102.2M |
| Shareholders’ equity | $96.0M | $98.0M | $86.3M | $94.5M | $94.7M |
From the company’s annual reports to the SEC. Each year links to its report.
Financials 29
- 10-Q Quarterly Report for period ending Mar 31, 2022
- 10-K/A Annual Report for period ending Dec 31, 2021
- 10-K Annual Report for period ending Dec 31, 2021
- 10-Q Quarterly Report for period ending Sep 30, 2021
- 10-Q Quarterly Report for period ending Jun 30, 2021
- 10-Q Quarterly Report for period ending Mar 31, 2021
- 10-K Annual Report for period ending Dec 31, 2020
- 10-Q Quarterly Report for period ending Sep 30, 2020
- 10-Q Quarterly Report for period ending Jun 30, 2020
- 10-Q Quarterly Report for period ending Mar 31, 2020
News 77
- 8-K Material agreement ended; Acquisition or sale completed; Delisting notice; Change to shareholder rights; Change in control; Director or officer change; Charter or bylaw change
- 8-K Shareholder vote results; Other events
- 8-K Other events
- 8-K Other events
- 8-K Financial results
- 8-K Material agreement; Other events
- 8-K Director or officer change
- 8-K Financial results
- 8-K Director or officer change
- 8-K Other events
Ownership 294
- SC 13G/A Major shareholder report (passive investor)
- SC 13G/A Major shareholder report (passive investor)
- SC 13D/A Major shareholder report
- SC 13G/A Major shareholder report (passive investor)
- 4 Change in insider ownership
- 4 Change in insider ownership
- 4 Change in insider ownership
- 4 Change in insider ownership
- 4 Change in insider ownership
- 4 Change in insider ownership
Prospectus 45
- S-8 POS Post-effective amendment to a S-8 registration statement
- S-8 POS Post-effective amendment to a S-8 registration statement
- S-8 POS Post-effective amendment to a S-8 registration statement
- S-8 POS Post-effective amendment to a S-8 registration statement
- S-8 POS Post-effective amendment to a S-8 registration statement
- S-8 POS Post-effective amendment to a S-8 registration statement
- S-8 POS Post-effective amendment to a S-8 registration statement
- S-8 POS Post-effective amendment to a S-8 registration statement
- S-8 POS Post-effective amendment to a S-8 registration statement
- S-8 POS Post-effective amendment to a S-8 registration statement
Proxies 21
- DEFM14A Definitive proxy statement relating to a merger, acquisition, or disposition
- PREM14A Preliminary proxy statement relating to a merger, acquisition, or disposition
- DFAN14A Definitive additional proxy soliciting materials filed by non-management including Rule 14(a)(12) material
- DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
- DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
- DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
- DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
- DEF 14A Definitive proxy statements
- DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
- DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
Other 61
- 15-12G Notice of termination of registration of a class of securities under Section 12(g)
- EFFECT Notice of Effectiveness
- EFFECT Notice of Effectiveness
- 25-NSE Removal from exchange listing
- POS AM Post-effective amendment to a registration statement that is not immediately effective upon filing
- POS AM Post-effective amendment to a registration statement that is not immediately effective upon filing
- EFFECT Notice of Effectiveness
- CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
- UPLOAD Letter (PDF)
- EFFECT Notice of Effectiveness